Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

September 01, 2012 (Vol. 32, No. 15)

Leveraging Synthetic Lethality for Cancer

Researchers Investigating a Class of Drugs that Could Short-Circuit Cancer Cells at Molecular Level

  • For the past few years, drugs exploiting synthetic lethality have gained attention as novel anticancer agents. Breast and ovarian cancers with mutated BRCA1 or 2, essential components of a pathway for repairing DNA double-strand breaks, provide a fundamental example of how synthetic lethality works. Because replicating DNA requires ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.